Comparison of Management and Outcomes in ERBB2-Low vs ERBB2-Zero Metastatic Breast Cancer in France.

Date publication

septembre 2022

Journal

JAMA network open

Auteurs

Membres identifiés du Cancéropôle Est :
Pr PETIT Thierry , Dr DESMOULINS Isabelle , Dr JOUANNAUD Christelle

Tous les auteurs :
de Calbiac O, Lusque A, Mailliez A, Bachelot T, Uwer L, Mouret-Reynier MA, Emile G, Jouannaud C, Gonçalves A, Patsouris A, Diéras V, Leheurteur M, Petit T, Cottu P, Ferrero JM, D'Hondt V, Desmoulins I, Mourato-Ribeiro J, Martin AL, Frenel JS

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/36107428

Résumé

ERBB2-low (ie, ERBB2 immunohistochemistry score of 1+ or 2+ in the absence of ERBB2 gene amplification) breast cancer (BC) is a new entity, with emerging dedicated treatments. Little is known about its prognosis and response to conventional therapy compared with ERBB2-zero breast tumors (ie, those with an immunohistochemistry score of 0).

Référence

JAMA Netw Open. 2022 09 1;5(9):e2231170